New clinical guidelines from the European Hematology Association and European Myeloma Network are transforming care for smoldering multiple myeloma, emphasizing risk stratification and early intervention. Concurrently, therapies targeting mismatch repair-deficient cancers and MET proto-oncogene alterations underline precision oncology advances. Innovations include novel estrogen receptor degraders outperforming fulvestrant in breast cancer and insights into epithelial–mesenchymal transition mechanisms fueling metastasis and therapy resistance, providing fresh targets for clinical management and drug development.